Click on headlines below to download research

GSK’s Sierra acquisition, read-across for Sareum
Sareum Holdings | 14/04/2022

GlaxoSmithKline (GSK) has announced the acquisition of Sierra Oncology, Sareum’s licensing partner for its CHK1 asset SRA737 (held in partnership…

Approaching the clinic
Sareum Holdings | 09/03/2022

Sareum’s H122 results (to end-December 2021) provided an update on the company’s progress with its therapeutic pipeline. With final toxicology…

Edison Open House Healthcare 2022
Sareum Holdings: Edison Open House Healthcare 2022 | 09/02/2022

Sareum Holdings is a UK-based drug development company, specialising in small molecule kinase inhibitors. • Tell us about your business model and…